Silexion Therapeutics Corp
No SEC Form 4 filings for $SLXN in the last 30 days.
See all $SLXN insider activity →Silexion Therapeutics (SLXN) priced a $2.5 million public offering of 3.85 million ordinary shares and Series E warrants at $0.65 per share, with warrants exercisable at $0.65 and expiring in five years. Net proceeds will fund its Phase 2/3 SIL204 trial and general purposes. SLXN fell 31% to $1.03.
Silexion Therapeutics (NASDAQ: SLXN) reported new preclinical results for its SIL204 siRNA in KRAS-mutant pancreatic and NSCLC cell lines. SIL204 increased FAS (CD95) expression and decreased HLA-G, supporting a multi-pathway immune-sensitization rationale for combining with anti-PD-(L)1 therapies. The company is advancing SIL204 in Phase 2/3 after starting a first clinical trial site at Tel Aviv Sourasky Medical Center in late July 2026.
Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002022416 00-0000000 0002022416 2026-07-31 2026-07-31 0002022416 us-gaap:CommonStockMember 2026-07-31 2026-07-31 0002022416 SLXN:WarrantsExercisableForOrdinarySharesMember 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND
Over the past 7 days, alphai's AI scored 1 news story mentioning SLXN (Silexion Therapeutics Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent SLXN coverage spans financial news, corporate actions and technology.
The dilutive financing and warrant terms are the immediate driver of SLXN’s sharp selloff, with near-term overhang into the Aug. 13 close.
The update strengthens the mechanistic rationale for SIL204 as a multi-pathway immune sensitizer and supports continued Phase 2/3 combination development with anti-PD-(L)1.
Board composition change may affect governance and committee dynamics, but the filing states no disagreement with company operations.
Trial initiation is a meaningful biotech catalyst, but near-term tradability depends on safety readouts and expansion milestones.
Approvals increase the likelihood warrants can be exercised and expand authorized shares, which can raise dilution over time.
alphai scores every news story that mentions SLXN with an AI model for sentiment and relevance, and aggregates insider trades from Silexion Therapeutics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Silexion Therapeutics (SLXN) priced a $2.5 million public offering of 3.85 million ordinary shares and Series E warrants at $0.65 per share, with warrants exercisable at $0.65 and expiring in five years. Net proceeds will fund its Phase 2/3 SIL204 trial and general purposes. SLXN fell 31% to $1.03.
4 min readSilexion Therapeutics (NASDAQ: SLXN) reported new preclinical results for its SIL204 siRNA in KRAS-mutant pancreatic and NSCLC cell lines. SIL204 increased FAS (CD95) expression and decreased HLA-G, supporting a multi-pathway immune-sensitization rationale for combining with anti-PD-(L)1 therapies. The company is advancing SIL204 in Phase 2/3 after starting a first clinical trial site at Tel Aviv Sourasky Medical Center in late July 2026.
4 min readSilexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0002022416 00-0000000 0002022416 2026-07-31 2026-07-31 0002022416 us-gaap:CommonStockMember 2026-07-31 2026-07-31 0002022416 SLXN:WarrantsExercisableForOrdinarySharesMember 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND
2 min readTel Aviv Sourasky Medical Center and Israeli biotech Silexion Therapeutics (Nasdaq: SLXN) announced a first-in-world clinical trial of SIL204, an siRNA therapy targeting KRAS mutations in pancreatic cancer. The study will enroll about 18 patients initially to assess safety, then expand, potentially to 166. SIL204 will be injected into tumors and combined with standard systemic treatment.
4 min readSilexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 12-31 0002022416 00-0000000 NASDAQ NASDAQ 0002022416 2026-07-21 2026-07-21 0002022416 slxn:OrdinarySharesParValue0135PerShareMember 2026-07-21 2026-07-21 0002022416 slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf1552500PerShareMember 2026-07-21 2026-07-21 UNITE
3 min readSilexion Therapeutics said Germany’s BfArM approved it to start a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, following a positive ethics opinion from the North Rhine Medical Association. The company also has Israel approval. Site activation is underway, with first patient dosing expected in the coming weeks.
4 min readShirvan Mitchell, CSO and CDO of Silexion Therapeutics (SLXN), reported selling 22,818 Ordinary Shares on March 26, 2026, at $1.36 per share. This transaction was a "sale-to-cover" to address tax liabilities from a fully vested restricted share unit grant received in February 2026. Following the sale, Mitchell directly holds 27,889 Ordinary Shares and an adjusted stock option for 478 Ordinary Shares.
2 min readSilexion Therapeutics (NASDAQ: SLXN) has received approval from the Israeli Ministry of Health to begin a Phase 2/3 clinical trial for SIL204, its drug candidate for locally advanced pancreatic cancer. The drug targets KRAS mutations, which are present in over 90% of pancreatic cancers, and has shown strong preclinical anti-tumor activity. Silexion plans to initiate human trials in Q2 2026 and expects to file for additional regulatory approvals in Germany and the EU by early 2027.
3 min readGrand Cayman, Cayman Islands, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Silexion Therapeutics Corp. ( "Silexion" or the "Company" ) , a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st ...
2 min readGrand Cayman, Cayman Islands, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Silexion Therapeutics Corp. ( "Silexion" or the "Company" ) , a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st ...
2 min read
